Brain Tumours

Summary

• Dabrafenib was well tolerated in pediatric patients • Phase 2 recommended doses were identified and different in children ≤12 years and children >12 years based on PK parameters • Radiographic responses (44%) and prolonged stable disease (19%) were seen across a number of tumor types driven by BRAFV600 mutations • The multistrata phase 2 component of trial is open and accruing around the world

115